LED Dental traces its roots back to the mid-1990s, when company founder Peter Whitehead began performing oral cancer research in conjunction with the British Columbia Cancer Agency (BCCA). In 2000, Peter and a fellow BCCA researcher were awarded patents for groundbreaking technologies they developed for detecting oral cancer. Peter ultimately formed LED Medical Diagnostics Inc. and it operating subsidiary, LED Dental, to focus on the advancement of these technologies. LED Dental, in concert with the BCCA, ultimately co-developed the patented VELscope® Vx Enhanced Oral Assessment System, a tissue fluorescence visualization technology that received FDA and Health Canada clearance in 2006. Since then, there have been more than 12,000 VELscope Vx systems sold globally, and they have been used to perform more than 25 million oral examinations worldwide. In early 2014, LED Dental entered the dental imaging market in response to the explosive growth in dental CAD/CAM and the shift away from film-based systems to faster, more efficient and higher quality digital imaging solutions. We serve a previously unmet market demand for "open architecture" digital imaging technologies and we are rapidly growing a comprehensive portfolio of state-of-the-art offerings to meet this demand. Guiding our growth is a management team comprised some of the best minds from both the clinical and business sides of the dental industry. Drawing upon their decades of collective experience, they are identifying target technologies and product lines for our portfolio; building and managing our operations and sales teams; and developing a streamlined chain of communication that enables us to listen closely and serve the needs of our customers - and, in turn, enabling these clients to best serve their patients.
Keystone Dental is a Burlington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
InfraScan, Inc. is a medical device company that focuses on developing, commercializing, and distributing hand-held diagnostic devices for head injury and stroke assessment based on near infrared (NIR) technology. The Infrascanner enables clinicians to detect effectively, conveniently, and accurately intracranial bleeding in patients with head trauma. Intracranial hematomas are an important treatable cause of secondary brain injury in patients with head trauma. Recent statistics from Iraq shows that 30% of all wounded in action have head injuries; of them 40% have brain hematomas. Dr. Britton Chance (University of Pennsylvania) and Dr. Claudia Robertson (Baylor College of Medicine) invented a NIR system for detection of brain Hematomas and tested it successfully in 305 patients in Baylor. An entrepreneurial team formed a company around this technology in Collaboration with Drexel University and won the Wharton Business Plan competition in April 2004 and the second prize at the global business plan competition in Singapore in October 2004. Office of Naval Research funded the company in May 2004. The company also attracted $1.5M in funding from BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania, from Ben Franklin Technology Partners of Southeastern Pennsylvania, and from Philadelphia Industrial Development Corporation. A multicenter clinical study to support an FDA submission started in July 2006, and on February 2008 an application was submitted to the FDA. After 4 years of review, the FDA cleared Infrascanner Model 1000 as a DeNovo medical technology in December 2011. In January 2013 the FDA cleared the 510(k) of Infrascanner Model 2000.
Atlanta Pediatric Therapy is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cadent is a Carlstadt, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.